PH12017501413A1 - Substituted nucleoside derivatives useful as anticancer agents - Google Patents
Substituted nucleoside derivatives useful as anticancer agentsInfo
- Publication number
- PH12017501413A1 PH12017501413A1 PH12017501413A PH12017501413A PH12017501413A1 PH 12017501413 A1 PH12017501413 A1 PH 12017501413A1 PH 12017501413 A PH12017501413 A PH 12017501413A PH 12017501413 A PH12017501413 A PH 12017501413A PH 12017501413 A1 PH12017501413 A1 PH 12017501413A1
- Authority
- PH
- Philippines
- Prior art keywords
- anticancer agents
- derivatives useful
- substituted nucleoside
- nucleoside derivatives
- compounds
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119932P | 2015-02-24 | 2015-02-24 | |
| US201562213801P | 2015-09-03 | 2015-09-03 | |
| US201662279209P | 2016-01-15 | 2016-01-15 | |
| PCT/IB2016/050803 WO2016135582A1 (en) | 2015-02-24 | 2016-02-15 | Substituted nucleoside derivatives useful as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12017501413A1 true PH12017501413A1 (en) | 2018-01-29 |
Family
ID=55451515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12017501413A PH12017501413A1 (en) | 2015-02-24 | 2017-08-08 | Substituted nucleoside derivatives useful as anticancer agents |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10428104B2 (enExample) |
| EP (1) | EP3262057B1 (enExample) |
| JP (1) | JP6584521B2 (enExample) |
| KR (1) | KR20170119705A (enExample) |
| CN (1) | CN107278205A (enExample) |
| AU (2) | AU2016225133B2 (enExample) |
| BR (1) | BR112017017396A2 (enExample) |
| CA (1) | CA2921314A1 (enExample) |
| CL (1) | CL2017002155A1 (enExample) |
| CO (1) | CO2017008403A2 (enExample) |
| CR (1) | CR20170384A (enExample) |
| CU (1) | CU20170105A7 (enExample) |
| DO (1) | DOP2017000195A (enExample) |
| EA (1) | EA031895B1 (enExample) |
| ES (1) | ES2792899T3 (enExample) |
| GT (1) | GT201700189A (enExample) |
| IL (1) | IL253637A0 (enExample) |
| MX (1) | MX2017010844A (enExample) |
| NI (1) | NI201700095A (enExample) |
| PE (1) | PE20171449A1 (enExample) |
| PH (1) | PH12017501413A1 (enExample) |
| SG (1) | SG11201706050WA (enExample) |
| SV (1) | SV2017005514A (enExample) |
| TN (1) | TN2017000357A1 (enExample) |
| TW (1) | TWI622595B (enExample) |
| UA (1) | UA118315C2 (enExample) |
| UY (1) | UY36564A (enExample) |
| WO (1) | WO2016135582A1 (enExample) |
| ZA (1) | ZA201705092B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| JP6909799B2 (ja) * | 2016-03-10 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤として使用するための置換ヌクレオシドアナログ |
| AU2017230658B2 (en) | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| SI3512857T1 (sl) | 2016-09-14 | 2021-07-30 | Janssen Pharmaceutica Nv | Spiro biciklični zaviralci interakcije menin-MLL |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| AU2017338269B2 (en) | 2016-10-03 | 2021-03-25 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors |
| US10745409B2 (en) | 2016-12-15 | 2020-08-18 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
| WO2018152548A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152501A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018154104A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| EP3939986A1 (en) * | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US11524962B2 (en) | 2017-10-26 | 2022-12-13 | Prelude Therapeutics, Incorporated | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) |
| BR112020010815A2 (pt) | 2017-12-08 | 2020-11-10 | Janssen Pharmaceutica Nv | análogos espirobicíclicos |
| CU24621B1 (es) | 2017-12-13 | 2022-09-08 | Lupin Ltd | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| JP7328241B2 (ja) * | 2018-03-14 | 2023-08-16 | プレリュード セラピューティクス，インコーポレイティド | タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| EP3833669A4 (en) * | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
| KR20210129051A (ko) * | 2019-02-13 | 2021-10-27 | 프렐루드 테라퓨틱스, 인코포레이티드 | 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제 |
| CA3134779A1 (en) * | 2019-03-25 | 2020-10-01 | California Institute Of Technology | Prmt5 inhibitors and uses thereof |
| US12440506B2 (en) | 2019-04-05 | 2025-10-14 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| PH12021553082A1 (en) | 2019-06-10 | 2023-09-11 | Lupin Ltd | Prmt5 inhibitors |
| KR20220019766A (ko) | 2019-06-12 | 2022-02-17 | 얀센 파마슈티카 엔.브이. | 신규 스피로바이사이클릭 중간체 |
| PL4299135T3 (pl) | 2019-06-18 | 2025-11-12 | Pfizer Inc. | Pochodne benzizoksazolosulfonamidu |
| EP4031555A1 (en) | 2019-09-18 | 2022-07-27 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| JP7624985B2 (ja) | 2019-10-22 | 2025-01-31 | ルピン・リミテッド | Ｐｒｍｔ５阻害剤の組合せ医薬 |
| CN115135651A (zh) | 2019-12-03 | 2022-09-30 | 鲁皮恩有限公司 | 作为prmt5抑制剂的被取代的核苷类似物 |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| CA3192099A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak inhibitor |
| WO2022040172A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
| US20240101589A1 (en) * | 2020-10-08 | 2024-03-28 | Strom Therapeutics Limited | Inhibitors of mettl3 |
| CN112679505B (zh) * | 2020-12-25 | 2022-04-22 | 杭州澳赛诺生物科技有限公司 | 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法 |
| WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| JP2024526762A (ja) | 2021-07-12 | 2024-07-19 | インサイト・コーポレイション | Ｊａｋ阻害剤を調製するためのプロセス及び中間体 |
| US20250188110A1 (en) * | 2021-08-13 | 2025-06-12 | Albert-Ludwigs-Universität Freiburg | Specific small molecule inhibitors that block kmt9 methyltransferase activity and function |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795977A (en) * | 1989-09-15 | 1998-08-18 | Metabasis Therapeutics, Inc. | Water soluble adenosine kinase inhibitors |
| US5646128A (en) * | 1989-09-15 | 1997-07-08 | Gensia, Inc. | Methods for treating adenosine kinase related conditions |
| US5864033A (en) * | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| US6831069B2 (en) * | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| CA2495370A1 (en) * | 2002-08-15 | 2004-02-26 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
| EP2623104A1 (en) * | 2009-03-20 | 2013-08-07 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| WO2013009735A1 (en) * | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013044030A1 (en) * | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
| EP3160477A4 (en) * | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| AR104326A1 (es) * | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| WO2017024310A1 (en) * | 2015-08-06 | 2017-02-09 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
-
2016
- 2016-02-15 CN CN201680011823.1A patent/CN107278205A/zh active Pending
- 2016-02-15 UA UAA201708102A patent/UA118315C2/uk unknown
- 2016-02-15 BR BR112017017396A patent/BR112017017396A2/pt not_active Application Discontinuation
- 2016-02-15 EP EP16707209.9A patent/EP3262057B1/en active Active
- 2016-02-15 MX MX2017010844A patent/MX2017010844A/es unknown
- 2016-02-15 EA EA201791563A patent/EA031895B1/ru not_active IP Right Cessation
- 2016-02-15 TN TNP/2017/000357A patent/TN2017000357A1/en unknown
- 2016-02-15 CU CUP2017000105A patent/CU20170105A7/xx unknown
- 2016-02-15 JP JP2017544584A patent/JP6584521B2/ja not_active Expired - Fee Related
- 2016-02-15 PE PE2017001447A patent/PE20171449A1/es unknown
- 2016-02-15 AU AU2016225133A patent/AU2016225133B2/en not_active Ceased
- 2016-02-15 WO PCT/IB2016/050803 patent/WO2016135582A1/en not_active Ceased
- 2016-02-15 ES ES16707209T patent/ES2792899T3/es active Active
- 2016-02-15 SG SG11201706050WA patent/SG11201706050WA/en unknown
- 2016-02-15 CR CR20170384A patent/CR20170384A/es unknown
- 2016-02-15 KR KR1020177026762A patent/KR20170119705A/ko not_active Ceased
- 2016-02-17 US US15/045,679 patent/US10428104B2/en active Active
- 2016-02-19 TW TW105104968A patent/TWI622595B/zh not_active IP Right Cessation
- 2016-02-19 CA CA2921314A patent/CA2921314A1/en not_active Abandoned
- 2016-02-22 UY UY0001036564A patent/UY36564A/es not_active Application Discontinuation
-
2017
- 2017-07-24 IL IL253637A patent/IL253637A0/en unknown
- 2017-07-26 ZA ZA2017/05092A patent/ZA201705092B/en unknown
- 2017-07-28 NI NI201700095A patent/NI201700095A/es unknown
- 2017-08-08 PH PH12017501413A patent/PH12017501413A1/en unknown
- 2017-08-14 SV SV2017005514A patent/SV2017005514A/es unknown
- 2017-08-17 CO CONC2017/0008403A patent/CO2017008403A2/es unknown
- 2017-08-21 DO DO2017000195A patent/DOP2017000195A/es unknown
- 2017-08-24 GT GT201700189A patent/GT201700189A/es unknown
- 2017-08-24 CL CL2017002155A patent/CL2017002155A1/es unknown
-
2018
- 2018-12-11 AU AU2018278842A patent/AU2018278842A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| PH12018502535B1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| PH12019550235A1 (en) | Kinase inhibitors and uses thereof | |
| PH12018500457A1 (en) | New phenoxymethyl derivatives | |
| NZ739676A (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| PH12017500408A1 (en) | Heteroaryl compunds as btk inhibitors and uses thereof | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| MD20170070A2 (ro) | Derivaţi de chinazolină utilizaţi în tratamentul HIV | |
| TN2017000524A1 (en) | New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| NZ716840A (en) | Combination formulation of two antiviral compounds | |
| PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
| MX2017014035A (es) | Formas solidas novedosas. | |
| NZ763528A (en) | Heterocyclic gpr119 agonist compounds | |
| PH12018500852A1 (en) | Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use | |
| MX2018000515A (es) | Compuestos fluorados de cbd, composiciones y usos de los mismos. | |
| GB2564185A (en) | Process for the preparation of derivatives of benzodioxole | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs | |
| LV14852A (lv) | Triazolilpurīna atvasinājumi kā pretvīrusu preparāti |